Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma

International Journal of Cancer

Volumn 113, Issue 4, 2005, Pages 640-648

  Li, Gencong ^a   Sham, Jonathan ^b   Yang, Jiamei ^a   Su, Changqing ^a   Xue, Huibin ^a   Chua, Daniel ^b   Sun, Lichen ^a   Zhang, Qi ^a   Cui, Zhenfu ^a   Wu, Mengchao ^a   Qian, Qijun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adenovirus; Cancer therapy; Gene therapy; Hepatocellular carcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; E1B PROTEIN; ENDOSTATIN; ONCOLYTIC VIRUS; ONYX 015; PROTEIN P53;

ADENOVIRUS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; TRANSGENE; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MICE; MICE, NUDE; TETRAZOLIUM SALTS; THIAZOLES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 19944384542     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20581     Document Type: Article

References (44)

1. Kirn DH, McCormick F. Replicating viruses as selective cancer therapeutics. Mol Med Today 1996;2:519-27.
2. Sunamura M, Motoi F, Matsuno S. Restricted replication-component adenovirus: a novel strategy for cancer gene therapy. J Clin Oncol 2000;5:147-52.
3. Alemany R, Balague C, Curiel DT. Replication-selective viruses for caner therapy. Nat Biotechnol 2000;18:723-7.
4. Ring CJ. Cytolytic virus as potential anti-cancer agents. J Virol 2002;83:491-520.
5. Smith ER, Chiocca EA. Oncolytic viruses as novel anticancer agents: turning one scourge against another. Exp. Opin Invest Drugs 2000;9:311-27.
6. Somia N, Verma M. Gene therapy: trails and tribulations. Nat Rev Genet 2000;1:91-8.
7. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of the therapeutics. Nat Med 2001;7:33-8.
8. Biederer C, Ries S, Brandts CH, McCormick FM. Replication-selective viruses for caner therapy. Mol Med 2002;80:163-75.
9. Aghi M, Chou TC, Suling K, Breakfield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome p4502B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999;59:3861-5.
10. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998;9:1323-33.
11. Ries S, Korn WM. ONYX-015: mechanism of action and clinical potential of replication-selective adenovirus. Br J Cancer 2002;86:5-11.
12. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000;105:847-51.
13. Bischoff JR, Kirn DH, Williams A, Heis C, Horn S, Muna A, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
14. Nemumaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, et al. Selective replication oncolysis in p53 mutant tumours with ONYX-015, an E1B-55kDa gene deleted adenovirus, in patients with advanced head and neck cancer: a phase II trail. Cancer Res 2000;60:6359-66.
15. Nemumaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, Kuhn J, McCarty T, Landers S, Blackburn A, Romel L, Randlev B, et al. Phase II trail of intratumoral administration of ONYX-015, a replication-selective adenovirus in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-98.
16. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000;105:1169-72.
17. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci USA 1998;95:9064-6.
18. Cao Y. Antiangiogenic gene therapy. Gene Ther Regul 2000;1:123-39.
19. Venock AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994;12:1323-34.
20. Levin B, Amos C. Therapy of unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1294-6.
21. Qian QJ, Jonathan S, Che XY, Xu JG, Xue HB, Cui ZF, Zhu B, Wu MC. Gene-viral vectors; a promising way to target tumor cells and express anticancer genes simultaneously. Natl Med J China 2002;115:1213-7.
22. LaBarre DD, Lowy RJ. Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. J Virol Methods 2001;96:107-26.
23. American Veterinary Medical Association. 1993 Report of the AVMA panel on euthanasia. J Am Vet Med Assoc 1993;202:229-49.
24. Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery 1993;113:612-8.
25. Vollmer CM, Ribas A, Butterfield LH, Dissette VB, Andrews KJ, Eilber FC, Montejo LD, Chen AY, Hu B, Glaspy JA, McBride WH, Ecnomou JS. p53 selective and non-selective replication of E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 1999;59:4369-74.
26. Habib NA, Mitry RR, Sarraf CE, Jiao LR, Havlik R, Nicholls J, Jensen SL. Assessment of growth inhibition and morphological changes in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus. Cancer Gene Ther 2002;9:414-20.
27. Habib NA, Sarraf CE, Mitry RR, Havlik R, Nicholls J, Kelly M, Vernon CC, Gueret-Wardle D, Jiao LR, EL-Masry R, Salama H, Ahmed R, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001;12:219-26.
28. Habib NA, Salama H, Median A, Anis II, Aziz R, Sarraf CE, Mitry RR, Havlik R, Seth P, Hartwigsen J, Bhushan R, Nicholls J, et al. Clinical trail of E1b-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 2002;9:254-9.
29. Goldsmith KT, Dion LD, Curiel DT, Garver RI. Trans Elcomponent requirements for maximal replication of E1-defective recombinant adenovirus. Virology 1998;248:406-19.
30. Goodrum FD, Ornelles DA. P53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998;72:9479-90.
31. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998;72:9470-8.
32. Harada JN, Berk AJ. P53-independent and -dependent requirements for E1B-55k in adenovirus type 5 replication. J Virol 1999;73:5333-44.
33. Hay JG, Shapiro N, Sauthoff H, Heitner S, Phupakdi W, Rom W. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1B-55kD gene. Hum Gene Ther 1999;10:579-90.
34. Turnell AS, Grand RJ, Gallimore PH. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J Virol 1999;73:2074-83.
35. Heise C, Sampson-Johannes A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B-gene-attenuated adenovirus, causes tumor-specific cytolysis and efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.
36. Lee H, Kim J, Lee B, Chang JW, Ahn J, Park JO, Choi J, Yun CO, Kim BS, Kim JH. Oncolytic potential of E1B55 kDa-Deleted YKL-1 recombinant adenovirus: correlation with p53 functional status. Int J Cancer 2000;88:454-63.
37. Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, McCormick F, Korn WM. Loss of p14ARF in the tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 2000;6:1128-33.
38. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink 4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
39. Chang F, Syrjanen S, Syrjanen K. Implication of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
40. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999;17:343-8.
41. Chen QR, Kumar D, Stass SA, Mixson AJ. Liposomes complexed to plasmid encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999;59:3308-12.
42. O'Reilly MS, Boehm T, Shing Y, Fuhai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen B, Folkman J. Endostatin: an endogenous inhibitor or angiogenesis and tumor growth. Cell 1997;88:1-20.
43. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
44. Sauter BV, Martiner OM, Zhang WJ, Mandeli J, Woo SLC. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 2000;97:4802-7.